SAN

77.06

+0.75%↑

UCB

249.1

+3.15%↑

SHL.DE

36.68

+2.72%↑

ARGX

584.4

+1.67%↑

VIE

31.41

+3.49%↑

SAN

77.06

+0.75%↑

UCB

249.1

+3.15%↑

SHL.DE

36.68

+2.72%↑

ARGX

584.4

+1.67%↑

VIE

31.41

+3.49%↑

SAN

77.06

+0.75%↑

UCB

249.1

+3.15%↑

SHL.DE

36.68

+2.72%↑

ARGX

584.4

+1.67%↑

VIE

31.41

+3.49%↑

SAN

77.06

+0.75%↑

UCB

249.1

+3.15%↑

SHL.DE

36.68

+2.72%↑

ARGX

584.4

+1.67%↑

VIE

31.41

+3.49%↑

SAN

77.06

+0.75%↑

UCB

249.1

+3.15%↑

SHL.DE

36.68

+2.72%↑

ARGX

584.4

+1.67%↑

VIE

31.41

+3.49%↑

Search

Opmobility

Avatud

SektorTervishoid

14.6 7.43

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.59

Max

14.89

Põhinäitajad

By Trading Economics

Sissetulek

5M

95M

Müük

-448M

4.9B

P/E

Sektori keskmine

11.262

57.833

Dividenditootlus

3.3

Kasumimarginaal

1.945

Töötajad

28,258

EBITDA

72M

456M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+9.36% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.30%

2.47%

Turustatistika

By TradingEconomics

Turukapital

-253M

2.1B

Eelmine avamishind

7.17

Eelmine sulgemishind

14.6

Uudiste sentiment

By Acuity

50%

50%

144 / 350 Pingereas Healthcare

Opmobility Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. märts 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. märts 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. märts 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. märts 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. märts 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. märts 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Global Equities Roundup: Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. märts 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. märts 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. märts 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. märts 2026, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. märts 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. märts 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. märts 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. märts 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. märts 2026, 21:10 UTC

Uudisväärsed sündmused

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. märts 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk
Tulu
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Opmobility Prognoos

Hinnasiht

By TipRanks

9.36% tõus

12 kuu keskmine prognoos

Keskmine 15.31 EUR  9.36%

Kõrge 21 EUR

Madal 9.2 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi Opmobility 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

3

Osta

1

Hoia

3

Müü

Sentiment

By Acuity

144 / 350 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Opmobility

OPmobility SE engages in the manufacture and sale of exterior vehicle lighting systems, batteries, and electrification systems for electric mobility in Europe, North America, China, rest of Asia, South America, the Middle East, and Africa. The company operates through three segments: Exterior Systems, Modules, and Powertrain. Its Exterior Systems segment provides intelligent exterior systems; and automotive lighting systems, headlights, and signal lighting to intelligent, and other lighting products. The company's Powertrain segment offers clean energy systems comprising energy storage and emission reduction systems for various types of gasoline, diesel, hybrid, and plug-in hybrid powertrains; designs and manufactures battery systems, electronics, and power electronics components for electric mobility of trucks, buses, trains, and construction machineries. This segment also designs and manufactures hydrogen solutions, including high-pressure fuel tanks, fuel cell stacks, and integrated systems. Its Modules segment engages in the design, development, and assemble of modules (HBPO). In addition, the company provides intelligent exterior systems, including bumpers, tailgates and spoilers, and body panels; onboard energy storage and emission reduction systems comprising selective catalytic reduction and fuel systems, and filling pipes. Further, it offers modules and personalization products, which include front-end module, active grille shutter, active rollo, and interior and charge lid modules; and lighting solutions, including interior, body shell, and front and signal lighting, as well as projection system and lighting electronics. The company was formerly known as Compagnie Plastic Omnium SE and changed its name to OPmobility SE in March 2024. The company was founded in 1946 and is headquartered in Levallois-Perret, France. OPmobility SE is a subsidiary of Burelle SA.
help-icon Live chat